A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease.

摘要: PURPOSE. To investigate the therapeutic efficacy of periocular vaccination with herpes simplex virus (HSV) recombinant glycoprotein D from HSV-I (gD1) or HSV-2 (gD2) in decreasing HSV-induced recurrent dendritic keratitis and ocular shedding rabbits latently infected HSV-I. METHODS. Rabbits HSV-1 were vaccinated periocularly (by subconjunctival injection) gD1 adjuvant, gD2 adjuvant alone. Eyes examined daily for 49 days herpetic infectious shedding. RESULTS. In both groups, a significantly decreased number eyes exhibited recurrences compared adjuvant-treated control (gD1 group, 27/1372, [2%]; 24/1274, control, 54/1274 [4%] P < 0.005). gD1-vaccinated group (44/1308 [3.4%]; = 0.01), but not those gD2-vaccinated (71/1274 [5.6%]; 0.93), had viral (positive cultures total cultures) (69 1275 [5.4%]). CONCLUSIONS. Recurrent corneal disease was reduced by local vaccination. The vaccine may be more efficacious against HSV-1-induced than Its appeared to longer lasting its spontaneous heterotypic as homotypic disease, whereas much This is first report any animal model successful disease. These results support concept that development recurrence humans possible.